Biogen Inc. research snapshot
BIIB AI stock analysis currently reads Biogen Inc. as a profitable biopharma turnaround where the growth portfolio now generates more revenue than legacy multiple sclerosis products, the Apellis acquisition closed in May 2026, and the late-stage pipeline is entering a heavy data flow. At the July 31, 2026 data cutoff, BIIB closed near $202.95 with an implied market capitalization of about $29.99 billion. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$202.95
Market cap
$29.99 billion
AI score
66 / 100
Rating
Growth portfolio-led turnaround with rising evidence, medium-high confidence
Trend status
Bullish technical posture with price above all key moving averages
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Biogen sells specialty medicines in neuroscience, rare disease, specialized immunology, biosimilars, and Alzheimer collaboration economics. | Medium-high |
| Moat | The moat comes from scientific know-how, patents, regulatory experience, physician relationships, disease-area expertise, and global commercial scale, but product exclusivity can decay. | Medium |
| Management | Christopher Viehbacher has shifted Biogen toward cost discipline, portfolio focus, business development, and late-stage pipeline rebuilding, and closed the Apellis acquisition in May 2026. | Medium |
| Financial trend | Q2 2026 total revenue rose 3% to $2.736 billion with growth portfolio revenue up 24% year over year, while GAAP diluted EPS fell to $0.66 on Apellis-related charges and non-GAAP diluted EPS was $3.60. | High |
| Valuation | Using the reported 2026 non-GAAP EPS guidance midpoint of $12.50, BIIB traded near 16.2x forward non-GAAP EPS, near 12.4x the underlying midpoint of $16.35, and about 11.1x trailing free cash flow per share. | Medium-high |
| Technical trend | Daily technicals turned constructive: price closed above the 20-day, 50-day, and 200-day moving averages with a neutral RSI near 50 and positive MACD. | Medium |
| Risk level | Main risks are MS product erosion, elevated leverage from the Apellis deal, clinical failures, Leqembi adoption limits, acquisition integration, and portfolio concentration. | Medium-high |
| AI confidence | High for descriptive research and calculations. Lower for exact stock outcomes because biotech stocks react sharply to trial, FDA, reimbursement, and M&A news. | High data confidence |
| Investment certainty | Medium-low certainty. BIIB is financially solid and technically improving, but the stock needs evidence that growth products and pipeline assets can restart durable earnings growth. | Medium-low |
BIIB AI stock forecast
The BIIB AI stock forecast uses scenario math around the $202.95 quote and Biogen 2026 underlying non-GAAP EPS guidance of $15.85 to $16.85 before one-time transaction charges. The audited three-year framework produced a bearish area near $154, a base area near $258, and a bullish area near $339, in line with the analyst consensus average target near $234 and a wide low-to-high analyst range.
$325 to $345
More likely if the growth portfolio keeps growing around 20%, litifilimab, felzartamab, and zorevunersen readouts succeed, Apellis synergies of at least $250 million materialize, and the market pays about 16x forward earnings.
$248 to $268
More likely if underlying non-GAAP EPS compounds around low-to-mid single digits, MS erosion stays manageable, Apellis becomes accretive in 2027 as guided, and BIIB holds a 13x to 14x earnings multiple.
$145 to $165
More likely if growth products disappoint, MS decline accelerates, important trials fail, Alzheimer adoption stays constrained, leverage pressures the balance sheet, or investors compress the multiple toward 10x earnings.
BIIB AI technical analysis
BIIB AI technical analysis turned bullish as of the July 31, 2026 cutoff. Price closed at $202.95 above the 20-day average near $202.76, the 50-day average near $200.52, and the 200-day average near $183.35, with 14-day RSI near 50.10 and a positive MACD, after a 60% gain over the trailing year.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $202.95 | Close used for market cap math at the July 31, 2026 cutoff. |
| Near support | $193 to $202 | The 20-day moving average near $202.76 and the lower Bollinger band near $193.47 define the nearest support zone. |
| Near resistance | $212 to $219 | The upper Bollinger band near $212.05 and the 20-day high near $218.59 are the first resistance references. |
| 50-day moving average | $200.52 | Price was above this level, confirming the intermediate-term recovery attempt. |
| 200-day moving average | $183.35 | Price remained well above the 200-day moving average, keeping the longer-term uptrend intact. |
| Momentum | 14-day RSI 50.10, MACD positive | RSI was neutral, leaving room in both directions, and MACD was slightly positive with the histogram at 0.16. |
| Volume | About 1.06 million intraday shares | The July 31 snapshot showed below-average volume at about 0.72x the 20-day average, suggesting light conviction in the pullback. |
| Volatility | High event-driven biopharma volatility | ATR near $7.89 was about 3.9% of price; expect larger moves around earnings, FDA decisions, trial readouts, reimbursement updates, and M&A news. |
| Invalidation | Close below $193, then failed reclaim of $219 | A break below the 20-day zone would challenge the short-term setup. A failed reclaim of the 52-week high would keep the range in play. |
BIIB AI trading strategy
The BIIB AI trading strategy is a rules-based research framework for an event-driven biopharma turnaround. It is not personal advice and should be paired with live quotes, filings, position sizing, and clinical or regulatory calendar checks.
Watch for BIIB to hold above the 50-day moving average and reclaim the $212 to $219 resistance zone with volume confirmation before treating the breakout as durable.
A close below the 20-day moving average or a failed reclaim of the 52-week high should invalidate the short-term setup.
If BIIB pulls back toward the $193 to $202 support zone without a new clinical, reimbursement, or guidance problem, compare the price reaction with growth portfolio sales and pipeline evidence.
Do not average down without a defined loss limit because a negative trial or regulatory update can turn support into a thesis break.
Track growth portfolio revenue, Leqembi adoption, Skyclarys, Zurzuvae, Syfovre, Empaveli, Spinraza high dose, MS erosion, non-GAAP EPS guidance, free cash flow, Apellis integration and synergies, and late-stage readouts.
Reduce confidence if earnings depend mainly on cost cuts, acquired IPR&D adjustments, or multiple expansion instead of durable product revenue growth.
Investment research summary
Biogen converts specialized biology, clinical development, regulatory approvals, and neurologist or specialist access into medicine revenue for hard-to-treat diseases.
The moat is strongest where patents, clinical evidence, rare-disease expertise, physician trust, and global commercial infrastructure reinforce each other. It narrows when legacy products lose exclusivity or new therapies show better efficacy, safety, or convenience.
The thesis fails if MS erosion outruns growth products, if Alzheimer adoption remains slower than expected, if late-stage assets fail, or if the Apellis deal adds leverage without durable earnings growth.
Management has emphasized cost discipline, pipeline focus, and external business development, including the May 2026 close of Apellis. Future judgment depends on capital allocation, trial outcomes, Apellis integration and synergies, and whether savings are reinvested into high-return assets.
Biopharma benefits from aging populations, genetic medicine, biologics, and unmet need, but the industry also carries patent cliffs, reimbursement pressure, binary clinical outcomes, and political pricing risk.
BIIB is no longer priced like a high-growth compounder, but the forward multiple on underlying earnings is reasonable. Margin of safety depends on whether current earnings are durable and whether the growth portfolio and pipeline can restart growth without destroying owner earnings.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BIIB price | $202.95 | Market quote snapshot | July 31, 2026 |
| Market capitalization | $29.99 billion, verified as $202.95 x 147.75 million shares | financial_rigor.py market cap verification | July 31, 2026 |
| Q2 2026 total revenue | $2.736 billion, up 3% year over year | Biogen Q2 2026 earnings release | July 29, 2026 |
| Q2 2026 GAAP and non-GAAP diluted EPS | $0.66 GAAP, $3.60 non-GAAP (beat consensus of $2.94) | Biogen Q2 2026 earnings release | July 29, 2026 |
| 2026 non-GAAP EPS guidance | Reported $12.00 to $13.00; underlying $15.85 to $16.85 before about $3.00 of transaction charges and about $0.85 of Apellis dilution | Biogen Q2 2026 earnings release | July 29, 2026 |
| Cash and debt at June 30, 2026 | $1.285 billion cash, about $8.1 billion total debt, net debt about $6.8 billion | Biogen Q2 2026 earnings release | July 29, 2026 |
| FY2025 revenue and net income | $9.891 billion revenue, $1.293 billion net income attributable to Biogen | Macrotrends and Biogen 2025 Annual Report | July 31, 2026 |
| Valuation check | 16.2x reported 2026 guidance midpoint, 12.4x underlying 2026 midpoint, 11.1x trailing FCF per share, 1.59x book value | financial_rigor.py valuation verification | July 31, 2026 |
| Analyst consensus | Buy, average price target $234.35, range $157 to $300, 36 analysts | S&P Global Market Intelligence via StockAnalysis | July 31, 2026 |
| Technical snapshot | SMA20 $202.76, SMA50 $200.52, SMA200 $183.35, RSI 50.10, MACD histogram 0.16 | Yahoo Finance Chart API via technical_analysis.py | July 31, 2026 |
This BIIB AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, technical data, and third-party sources as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, clinical data, regulatory events, M&A updates, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
